Healthcare led the S&P 500 on the first session after Democrats won both chambers of Congress: XLV +3.1% vs the index's +1.6%, with XBI and NBI each +2.7% and BBC +1.9%. Hospitals and Medicaid insurers moved most (Centene +12.6%, HCA +10.3%) and large pharma rose (J&J +3.8%, AbbVie +3.1%, Novo +5.0%); Bernstein flagged delayed Medicaid cuts and Citi expects existing MFN deals to hold.

The Dow had its best post-midterm session in 44 years as oil fell, while the Nasdaq 100 lagged at +0.9% on concern that a Democratic Congress could slow AI data-center buildout; the Russell 2000 added 1.6%.

Boehringer Ingelheim will pay Sino Biopharmaceutical (now SBP Group) $358M upfront and near-term for options on six preclinical cancer programs (ADCs and T-cell engagers), five from LaNova Medicines and one from Beijing Tide; option exercise and milestones take the total past $7B (Fierce Biotech puts it at $7.4B), plus tiered royalties.

Why it matters: Roughly 5% of the headline value lands near-term, and none of the six programs has dosed a patient: SBP runs early development and Boehringer opts in only after undisclosed clinical milestones, so most of the $7B is contingent twice over. Four assets carry rights ex-certain Asian markets; two are global. This is the pair's second oncology pact since 2024, after Boehringer's $1.26B Simcere TL1A/IL-23 licence in January and its new Shanghai R&D center in October. Option-gated preclinical structures keep China sourcing cheap while Treasury's draft COINS rules sit open for comment to 7 December. Licensing is outside that rule's scope; a NewCo or equity leg would not be.

Source: Endpoints

More: Fierce Biotech; BioSpace

CVS Health plans a tax-free separation by 1H28 into a healthcare solutions company (Aetna, CVS Caremark, CVS Specialty, Oak Street, Signify) led by David Joyner and CVS Pharmacy (~9,000 stores, mail pharmacy, MinuteClinic) led by Prem Shah. In the same-day Q3 release, revenue was $108.4B (+5.4%) and adj EPS $2.09 vs $1.60, and 2026 adj EPS guidance rose to at least $8.20 from $7.90-8.10.

Why it matters: What stays together matters more to drugmakers than what leaves. Caremark, which runs benefits for about 87 million members, stays bolted to Aetna and CVS Specialty, so the insurer-PBM integration that drives rebate negotiations survives the split. The 9,000-store retail arm goes independent and says it will partner with other payers, PBMs and manufacturers, which makes it a possible neutral channel for cash-pay and direct-to-patient programs like Lilly's. Timing is the catch: the separation needs a Form 10, tax confirmation and board sign-off, and lands in 1H28, after the DOL's PBM fee-disclosure rule takes effect on 1 July 2027. Caremark absorbs that rule inside the bigger company first.

Source: Endpoints

More: CVS separation release; CVS Q3 release

AbbVie took global rights to NXE0033744, an oral gut-restricted EP4 receptor agonist that has completed Phase 1 in ulcerative colitis, for $100M upfront, up to $1.37B in milestones (up to $1.47B total) and tiered royalties. Nxera had culled the program in its November 2025 restructuring.

Why it matters: AbbVie is paying $100M for an asset its owner cut a year ago, which says more about AbbVie's IBD plan than about Nxera's science. The EP4 agonist acts on the intestinal epithelium rather than on immune signalling, and Jefferies expects it to end up in combinations, the same logic as ABBV-466, AbbVie's Skyrizi plus α4β7 Phase 2 in Crohn's. Skyrizi did $5.8B in Q3, so a low-exposure oral add-on protects the franchise as oral α4β7 rivals such as Gilead's emvistegrast advance. The data are thin: Phase 1 only, no efficacy disclosed. Nxera books the cash against a 2026 forecast now at the top of its ¥48.8B range.

Source: Endpoints

More: Fierce Biotech; BioSpace

Spyre dropped SPY072 (long-acting anti-TL1A) in rheumatic disease after the SKYWAY Phase 2 missed its primary endpoint in psoriatic arthritis and axial spondyloarthritis and RA benefit was too small to advance; an HS pivotal program is planned for 2027. — Endpoints

Ideaya is closing the Phase 3 OptimUM-010 neoadjuvant darovasertib trial in uveal melanoma over site activation and enrollment problems, saving an estimated $100-125M; the metastatic darovasertib + crizotinib NDA was filed in Q3. — Ideaya Q3 release

Madrigal's former head of clinical development filed a whistleblower lawsuit alleging senior leadership censored serious liver-injury data on Rezdiffra and retaliated when the concern was raised. — Fierce Pharma

Kamau's revamped sickle cell gene-editing therapy nula-cel 2.0 showed no pain crises or transfusion needs in its first three patients; US launch is targeted for 2028. — Endpoints

Novo won't launch CagriSema in Europe for "a couple of years," its CFO said. — Endpoints

With Democrats taking the Senate, Bernie Sanders may gain outsized leverage over FDA funding and the next PDUFA reauthorization. — STAT

Ivonescimab won NMPA priority review with chemotherapy in first-line biliary tract cancer. — PR Newswire

Boehringer Ingelheim / SBP Group (Sino Biopharmaceutical): options on six preclinical ADC and T-cell engager programs (LaNova, Beijing Tide), $358M upfront and near-term, more than $7B with opt-ins and milestones, tiered royalties. — Fierce Biotech

AbbVie / Nxera: global licence to NXE0033744 (oral gut-restricted EP4 agonist, Phase 1 UC), $100M upfront, up to $1.37B milestones, tiered royalties. — BioSpace

United Therapeutics / Arena (Pfizer): $525M lump sum, paid 3 Nov, eliminates low-double-digit royalties on ralinepag; milestone obligations remain, and the payment is booked as Q4 R&D. — UTHR 10-Q

No notable private biotech financings since yesterday's edition.

Lyell Immunopharma (LYEL): ~$80M private placement, 7.43M shares at $10.77 to institutional investors (no lead named), signed 3 Nov and closed ~4 Nov, ahead of ronde-cel BLA plans. — Lyell 8-K

A NEJM commentary examines triple incretin agonists across obesity, osteoarthritis, and sleep apnea. — NEJM

Nature RDD reviewed why checkpoint inhibitor combinations often stall between trials and approval. — Nature RDD